SEATTLE--(BUSINESS WIRE)--Aug. 9, 2006--Northstar Neuroscience, Inc. (Nasdaq:NSTR) today reported that planned investments in its cortical stimulation platform and expansion of its clinical trials resulted in a net loss of $10.1 million for the quarter ended June 30, 2006 compared to a net loss of $3.4 million for the quarter ended June 30, 2005. The Company also reported that cash, cash equivalents and investments increased to $114.0 million at June 30, 2006 compared to $20.2 million at December 31, 2005 and that all outstanding debt had been repaid as of June 30, 2006.
